<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p174" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_174{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_174{left:306px;bottom:30px;}
#t3_174{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_174{left:346px;bottom:30px;}
#t5_174{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_174{left:517px;bottom:30px;}
#t7_174{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_174{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_174{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_174{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_174{left:35px;bottom:777px;letter-spacing:0.06px;word-spacing:0.12px;}
#tc_174{left:35px;bottom:754px;letter-spacing:0.1px;word-spacing:0.09px;}
#td_174{left:35px;bottom:731px;letter-spacing:0.03px;word-spacing:0.15px;}
#te_174{left:35px;bottom:707px;letter-spacing:0.02px;word-spacing:0.17px;}
#tf_174{left:35px;bottom:684px;letter-spacing:0.22px;word-spacing:-0.03px;}
#tg_174{left:35px;bottom:645px;letter-spacing:0.09px;word-spacing:0.09px;}
#th_174{left:35px;bottom:622px;letter-spacing:0.06px;word-spacing:0.12px;}
#ti_174{left:35px;bottom:599px;letter-spacing:0.08px;word-spacing:0.11px;}
#tj_174{left:207px;bottom:606px;}
#tk_174{left:252px;bottom:599px;letter-spacing:0.05px;word-spacing:0.13px;}
#tl_174{left:35px;bottom:575px;letter-spacing:0.03px;word-spacing:0.16px;}
#tm_174{left:298px;bottom:575px;}
#tn_174{left:308px;bottom:575px;letter-spacing:0.18px;word-spacing:0.01px;}
#to_174{left:35px;bottom:552px;letter-spacing:0.08px;word-spacing:-0.76px;}
#tp_174{left:35px;bottom:529px;letter-spacing:0.04px;word-spacing:0.15px;}
#tq_174{left:35px;bottom:506px;letter-spacing:0.04px;word-spacing:-0.47px;}
#tr_174{left:450px;bottom:513px;letter-spacing:-0.01px;}
#ts_174{left:472px;bottom:506px;letter-spacing:0.25px;word-spacing:-0.68px;}
#tt_174{left:35px;bottom:482px;letter-spacing:0.16px;word-spacing:-1.12px;}
#tu_174{left:35px;bottom:459px;letter-spacing:0.14px;word-spacing:0.05px;}
#tv_174{left:35px;bottom:436px;letter-spacing:0.07px;word-spacing:0.24px;}
#tw_174{left:35px;bottom:413px;letter-spacing:0.14px;word-spacing:-0.36px;}
#tx_174{left:35px;bottom:390px;letter-spacing:0.07px;word-spacing:-1.12px;}
#ty_174{left:35px;bottom:366px;letter-spacing:0.13px;word-spacing:0.06px;}
#tz_174{left:211px;bottom:374px;letter-spacing:-0.01px;}
#t10_174{left:235px;bottom:366px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t11_174{left:35px;bottom:343px;letter-spacing:-0.1px;}
#t12_174{left:71px;bottom:351px;letter-spacing:-0.01px;}
#t13_174{left:94px;bottom:343px;letter-spacing:0.06px;word-spacing:0.13px;}
#t14_174{left:35px;bottom:320px;letter-spacing:0.19px;}
#t15_174{left:438px;bottom:327px;letter-spacing:-0.01px;}
#t16_174{left:461px;bottom:320px;letter-spacing:0.14px;word-spacing:0.04px;}
#t17_174{left:35px;bottom:297px;letter-spacing:0.06px;word-spacing:0.12px;}
#t18_174{left:35px;bottom:273px;letter-spacing:0.13px;word-spacing:-0.5px;}
#t19_174{left:35px;bottom:250px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1a_174{left:35px;bottom:227px;letter-spacing:0.11px;word-spacing:-0.6px;}
#t1b_174{left:35px;bottom:204px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1c_174{left:561px;bottom:211px;letter-spacing:-0.01px;}
#t1d_174{left:35px;bottom:163px;letter-spacing:0.07px;word-spacing:-1px;}
#t1e_174{left:35px;bottom:140px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1f_174{left:35px;bottom:117px;letter-spacing:0.14px;word-spacing:0.04px;}
#t1g_174{left:35px;bottom:94px;letter-spacing:0.16px;word-spacing:-0.89px;}
#t1h_174{left:269px;bottom:101px;letter-spacing:-0.01px;}
#t1i_174{left:291px;bottom:94px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1j_174{left:483px;bottom:101px;letter-spacing:-0.01px;}
#t1k_174{left:506px;bottom:94px;letter-spacing:0.26px;word-spacing:-0.08px;}
#t1l_174{left:35px;bottom:71px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1m_174{left:618px;bottom:777px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1n_174{left:618px;bottom:754px;letter-spacing:0.02px;word-spacing:-0.79px;}
#t1o_174{left:618px;bottom:731px;letter-spacing:0.11px;word-spacing:-1.16px;}
#t1p_174{left:757px;bottom:738px;letter-spacing:-0.01px;}
#t1q_174{left:779px;bottom:731px;letter-spacing:0.03px;word-spacing:-1.08px;}
#t1r_174{left:618px;bottom:707px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1s_174{left:618px;bottom:684px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1t_174{left:1054px;bottom:692px;letter-spacing:0.09px;}
#t1u_174{left:618px;bottom:661px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1v_174{left:618px;bottom:638px;letter-spacing:-0.02px;}
#t1w_174{left:673px;bottom:645px;letter-spacing:-0.01px;}
#t1x_174{left:697px;bottom:638px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1y_174{left:618px;bottom:614px;letter-spacing:0.1px;word-spacing:-0.04px;}
#t1z_174{left:618px;bottom:591px;letter-spacing:0.15px;word-spacing:0.03px;}
#t20_174{left:618px;bottom:568px;letter-spacing:0.04px;word-spacing:-0.91px;}
#t21_174{left:618px;bottom:545px;letter-spacing:-0.01px;word-spacing:-0.73px;}
#t22_174{left:618px;bottom:522px;letter-spacing:0.08px;word-spacing:0.11px;}
#t23_174{left:618px;bottom:498px;letter-spacing:0.03px;word-spacing:0.15px;}
#t24_174{left:618px;bottom:475px;letter-spacing:0.17px;word-spacing:0.02px;}
#t25_174{left:1054px;bottom:483px;letter-spacing:0.1px;}
#t26_174{left:1099px;bottom:475px;letter-spacing:0.24px;word-spacing:-0.06px;}
#t27_174{left:618px;bottom:452px;letter-spacing:0.14px;word-spacing:0.04px;}
#t28_174{left:618px;bottom:430px;letter-spacing:0.07px;word-spacing:0.12px;}
#t29_174{left:618px;bottom:407px;letter-spacing:0.07px;word-spacing:0.12px;}
#t2a_174{left:618px;bottom:383px;letter-spacing:0.12px;word-spacing:-1.17px;}
#t2b_174{left:911px;bottom:383px;letter-spacing:0.09px;word-spacing:-0.52px;}
#t2c_174{left:618px;bottom:360px;letter-spacing:0.12px;word-spacing:-0.21px;}
#t2d_174{left:618px;bottom:337px;letter-spacing:0.11px;word-spacing:-0.47px;}
#t2e_174{left:618px;bottom:314px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2f_174{left:757px;bottom:321px;letter-spacing:-0.01px;}
#t2g_174{left:780px;bottom:314px;letter-spacing:0.18px;word-spacing:0.01px;}
#t2h_174{left:618px;bottom:291px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2i_174{left:618px;bottom:267px;letter-spacing:0.04px;word-spacing:0.14px;}
#t2j_174{left:618px;bottom:244px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2k_174{left:618px;bottom:221px;letter-spacing:0.12px;word-spacing:-0.09px;}
#t2l_174{left:618px;bottom:198px;letter-spacing:0.1px;word-spacing:0.08px;}
#t2m_174{left:618px;bottom:174px;letter-spacing:0.15px;word-spacing:-0.65px;}
#t2n_174{left:618px;bottom:151px;letter-spacing:0.09px;word-spacing:0.71px;}
#t2o_174{left:618px;bottom:111px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2p_174{left:1091px;bottom:118px;letter-spacing:-0.01px;}
#t2q_174{left:1115px;bottom:111px;letter-spacing:-0.31px;}
#t2r_174{left:618px;bottom:88px;letter-spacing:0.02px;word-spacing:0.17px;}
#t2s_174{left:1131px;bottom:95px;letter-spacing:0.1px;}
#t2t_174{left:618px;bottom:64px;letter-spacing:0.1px;word-spacing:0.08px;}
#t2u_174{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_174{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_174{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_174{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_174{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_174{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_174{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_174{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s7_174{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts174" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg174Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg174" style="-webkit-user-select: none;"><object width="1210" height="935" data="174/174.svg" type="image/svg+xml" id="pdf174" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_174" class="t s0_174">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_174" class="t s1_174">© </span>
<span id="t3_174" class="t s0_174">(NCCN </span>
<span id="t4_174" class="t s1_174">© </span>
<span id="t5_174" class="t s0_174">), All rights reserved. NCCN Guidelines </span>
<span id="t6_174" class="t s1_174">® </span>
<span id="t7_174" class="t s0_174">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_174" class="t s2_174">NCCN Guidelines Version 4.2024 </span>
<span id="t9_174" class="t s2_174">Head and Neck Cancers </span>
<span id="ta_174" class="t s3_174">MS-33 </span>
<span id="tb_174" class="t s4_174">findings). Study accrual was halted early due to unacceptable grade 5 </span>
<span id="tc_174" class="t s4_174">toxicities (two attributed to treatment) in the TORS arm. Long-term data </span>
<span id="td_174" class="t s4_174">regarding survival and disease outcomes from this trial are awaited. </span>
<span id="te_174" class="t s4_174">Additional randomized trials of minimally invasive transoral surgery or RT </span>
<span id="tf_174" class="t s4_174">for oropharyngeal cancer are ongoing (NCT02984410, NCT05144100). </span>
<span id="tg_174" class="t s4_174">Results from multiple phase II trials show that RT deintensification is </span>
<span id="th_174" class="t s4_174">associated with promising PFS rates in patients with p16-positive </span>
<span id="ti_174" class="t s4_174">oropharyngeal cancer. </span>
<span id="tj_174" class="t s5_174">444-448 </span>
<span id="tk_174" class="t s4_174">A phase II randomized trial of low-risk HPV- </span>
<span id="tl_174" class="t s4_174">associated oropharyngeal cancer (</span><span id="tm_174" class="t s6_174">≤</span><span id="tn_174" class="t s4_174">10 pack years, T1–2 N1 or T3 N0–1) </span>
<span id="to_174" class="t s4_174">demonstrated that de-escalated RT to 60 Gy with concurrent cisplatin was </span>
<span id="tp_174" class="t s4_174">associated with a 2-year PFS rate of 90.5%, and accelerated RT alone to </span>
<span id="tq_174" class="t s4_174">60 Gy was associated with a 2-year PFS rate of 87.6%. </span>
<span id="tr_174" class="t s5_174">449 </span>
<span id="ts_174" class="t s4_174">The former, but </span>
<span id="tt_174" class="t s4_174">not the latter, regimen met criteria for further study and is the subject of an </span>
<span id="tu_174" class="t s4_174">ongoing cooperative group phase II/III randomized trial on dose de- </span>
<span id="tv_174" class="t s4_174">escalation. Similarly, a nonrandomized phase II study of definitive RT to </span>
<span id="tw_174" class="t s4_174">60 Gy with or without concurrent cisplatin in 114 patients with T0–3 N0–2 </span>
<span id="tx_174" class="t s4_174">M0 p16-positive oropharyngeal cancer demonstrated a 2-year PFS of 86% </span>
<span id="ty_174" class="t s4_174">and 2-year OS of 95%. </span>
<span id="tz_174" class="t s5_174">447 </span>
<span id="t10_174" class="t s4_174">Analyses of QOL outcomes from one of these </span>
<span id="t11_174" class="t s4_174">trials </span>
<span id="t12_174" class="t s5_174">445 </span>
<span id="t13_174" class="t s4_174">showed that RT deintensification was associated with a quicker </span>
<span id="t14_174" class="t s4_174">and more robust return to baseline-level functioning. </span>
<span id="t15_174" class="t s5_174">450 </span>
<span id="t16_174" class="t s4_174">A prospective </span>
<span id="t17_174" class="t s4_174">phase II trial of initial TORS followed by risk-adapted adjuvant treatment </span>
<span id="t18_174" class="t s4_174">demonstrated a 2-year PFS rate of 96.9% for low-risk disease with TORS </span>
<span id="t19_174" class="t s4_174">alone, 94.9% for intermediate-risk disease with 50 Gy adjuvant RT, 96% </span>
<span id="t1a_174" class="t s4_174">for intermediate-risk disease with 60 Gy adjuvant RT, and 90.7% for high- </span>
<span id="t1b_174" class="t s4_174">risk disease with 66 Gy adjuvant RT with concurrent weekly cisplatin. </span>
<span id="t1c_174" class="t s5_174">451 </span>
<span id="t1d_174" class="t s4_174">Research on the impact of adverse pathologic features such as extranodal </span>
<span id="t1e_174" class="t s4_174">extension and number of involved nodes on outcomes in patients with </span>
<span id="t1f_174" class="t s4_174">p16-positive disease who have undergone resection is rapidly evolving. </span>
<span id="t1g_174" class="t s4_174">Analyses from the RTOG 9501 </span>
<span id="t1h_174" class="t s5_174">135 </span>
<span id="t1i_174" class="t s4_174">and EORTC 22931 trials, </span>
<span id="t1j_174" class="t s5_174">134 </span>
<span id="t1k_174" class="t s4_174">prior to the </span>
<span id="t1l_174" class="t s4_174">era of p16/HPV testing, showed that extranodal extension is associated </span>
<span id="t1m_174" class="t s4_174">with poor prognosis and demonstrated benefit to adjuvant systemic </span>
<span id="t1n_174" class="t s4_174">therapy/RT in patients with locally advanced SCCHN who have undergone </span>
<span id="t1o_174" class="t s4_174">surgical resection. </span>
<span id="t1p_174" class="t s5_174">136 </span>
<span id="t1q_174" class="t s4_174">Data suggesting equivalent outcomes of adjuvant RT </span>
<span id="t1r_174" class="t s4_174">and systemic therapy/RT for p16-positive oropharyngeal cancer with </span>
<span id="t1s_174" class="t s4_174">extranodal extension are restricted to retrospective trials, </span>
<span id="t1t_174" class="t s5_174">45,429,452-457 </span>
<span id="t1u_174" class="t s4_174">although clinical trials are being conducted to validate the revised AJCC </span>
<span id="t1v_174" class="t s4_174">staging </span>
<span id="t1w_174" class="t s5_174">391 </span>
<span id="t1x_174" class="t s4_174">for clinical decision-making. Secondary to lack of high-quality, </span>
<span id="t1y_174" class="t s4_174">prospective clinical evidence in the modern era, systemic therapy/RT is a </span>
<span id="t1z_174" class="t s4_174">category 2A option for both patients with p16-positive disease and p16- </span>
<span id="t20_174" class="t s4_174">negative disease and extranodal extension. Adjuvant systemic therapy/RT </span>
<span id="t21_174" class="t s4_174">remains a category 1 recommendation for patients with non-oropharyngeal </span>
<span id="t22_174" class="t s4_174">SCCHN who have extranodal extension. Since patients with p16-positive </span>
<span id="t23_174" class="t s4_174">oropharyngeal cancer have a generally favorable prognosis and may live </span>
<span id="t24_174" class="t s4_174">longer, toxicity and QOL are concerns for these patients. </span>
<span id="t25_174" class="t s5_174">433,434 </span>
<span id="t26_174" class="t s4_174">On the </span>
<span id="t27_174" class="t s4_174">other hand, they are also younger, with fewer comorbidities, so they can </span>
<span id="t28_174" class="t s4_174">probably tolerate combined adjuvant therapy better. Omitting systemic </span>
<span id="t29_174" class="t s4_174">therapy and administering radiotherapy alone is a category 2B option for </span>
<span id="t2a_174" class="t s4_174">patients with p16-positive cT0–2, cN0–</span><span id="t2b_174" class="t s6_174">1 disease (single node ≤3 cm) who </span>
<span id="t2c_174" class="t s4_174">have extranodal extension following surgery. For patients with positive or </span>
<span id="t2d_174" class="t s4_174">close margins, re-resection (if feasible), RT, and systemic therapy/RT are </span>
<span id="t2e_174" class="t s4_174">treatment options. </span>
<span id="t2f_174" class="t s5_174">151 </span>
<span id="t2g_174" class="t s4_174">For patients with other risk features such as pT3 or </span>
<span id="t2h_174" class="t s4_174">pT4 primary, one positive node greater than 3 cm or multiple positive </span>
<span id="t2i_174" class="t s4_174">nodes, nodal disease in levels IV or V, perineural invasion, vascular </span>
<span id="t2j_174" class="t s4_174">invasion, or lymphatic invasion, adjuvant treatment options include RT or </span>
<span id="t2k_174" class="t s4_174">systemic therapy/RT. If p16-positive disease, systemic therapy/RT in this </span>
<span id="t2l_174" class="t s4_174">setting is a category 2B option. If p16-negative disease that is pN1 </span>
<span id="t2m_174" class="t s4_174">following resection with no other adverse pathologic features present, RT </span>
<span id="t2n_174" class="t s4_174">may be considered. </span>
<span id="t2o_174" class="t s4_174">Based on results from the phase III randomized GORTEC trial </span>
<span id="t2p_174" class="t s5_174">181 </span>
<span id="t2q_174" class="t s4_174">and </span>
<span id="t2r_174" class="t s4_174">retrospective analyses from the National Cancer Database (NCDB), </span>
<span id="t2s_174" class="t s5_174">458,459 </span>
<span id="t2t_174" class="t s4_174">systemic therapy/RT is a treatment option for patients with p16-negative </span>
<span id="t2u_174" class="t s7_174">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
